Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:11 PM
Ignite Modification Date:
2025-12-24 @ 4:11 PM
NCT ID:
NCT06125366
Brief Summary:
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants:
* the safety of BAY1747846 when given at increasing single doses
* the level of BAY1747846 in the body over time when given at increasing single doses.
To answer the first question, the researchers compared the number and severity of medical problems the Japanese participants had after receiving BAY 1747846 at increasing doses and placebo respectively. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
To answer the second question, the researchers determined:
* the (average) total level of BAY1747846 in the body, also called AUC
* the (average) highest level of BAY1747846 in the body, also called Cmax
* how BAY1747846 is removed from the body, also called clearance (CL).
Study:
NCT06125366
Study Brief:
Protocol Section:
NCT06125366